{"protocolSection":{"identificationModule":{"nctId":"NCT01863277","orgStudyIdInfo":{"id":"0130-12"},"organization":{"fullName":"Wolfson Medical Center","class":"OTHER_GOV"},"briefTitle":"Safety Study of Melatonin in Stroke Patients","officialTitle":"A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke."},"statusModule":{"statusVerifiedDate":"2013-04","overallStatus":"UNKNOWN","lastKnownStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-07"},"primaryCompletionDateStruct":{"date":"2014-04","type":"ESTIMATED"},"studyFirstSubmitDate":"2013-05-22","studyFirstSubmitQcDate":"2013-05-24","studyFirstPostDateStruct":{"date":"2013-05-27","type":"ESTIMATED"},"lastUpdateSubmitDate":"2013-05-24","lastUpdatePostDateStruct":{"date":"2013-05-27","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Dr. Yair Lampl","investigatorTitle":"Prof. Yair Lampl","investigatorAffiliation":"Wolfson Medical Center"},"leadSponsor":{"name":"Wolfson Medical Center","class":"OTHER_GOV"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of the study is to evaluate the effect of Melatonin (in a dosage of 14mg daily) for a better clinical outcome in the period three days post stroke.","detailedDescription":"Stroke is the third most common cause of stroke. The cascade of event is separated into hyperacute,,acute,sub-acute and chronic. In the acute, sub acute state there are mechanisms of inflammation apoptotic death and effect of free radicals. Melatonin was proved to effect these mechanisms and to have a favourable effect in different diseases. The aim of the study is to prove That the use of Melatonin in a higher dosage may have a anti-destructive effect in stoke."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":140,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Melatonin","type":"ACTIVE_COMPARATOR","description":"Melatonin 14mg/daily given over 14 days","interventionNames":["Drug: Melatonin"]},{"label":"sugar pill","type":"PLACEBO_COMPARATOR","description":"sugar pill given over 14 days","interventionNames":["Drug: placebo"]}],"interventions":[{"type":"DRUG","name":"Melatonin","armGroupLabels":["Melatonin"]},{"type":"DRUG","name":"placebo","armGroupLabels":["sugar pill"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Improvement of at least one point on the MRS score","timeFrame":"3 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* within 72hours of ischemic stroke\n* age 18-80\n* both gender\n* ability to sign consent form\n\nExclusion Criteria:\n\n* intra-cerebral bleeding\n* tumour of brain\n* multiple sclerosis\n* s/p craniotomy\n* known allergy to melatonin","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"E. Wolfson Medical Center","city":"Holon","zip":"58100","country":"Israel","contacts":[{"name":"Yair Lampl, Prof","role":"CONTACT","phone":"+972-3-5028513","email":"y_lampl@hotmail.com"},{"name":"Mary Israelson","role":"CONTACT","phone":"+972-507-704618","email":"maryisraelson@gmail.com"},{"name":"Yair Lampl, Prof","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.01034,"lon":34.77918}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000008550","term":"Melatonin"}],"ancestors":[{"id":"D000000975","term":"Antioxidants"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000002492","term":"Central Nervous System Depressants"}],"browseLeaves":[{"id":"M11223","name":"Melatonin","asFound":"Ketamine","relevance":"HIGH"},{"id":"M3982","name":"Antioxidants","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"T410","name":"Melatonin","asFound":"Ketamine","relevance":"HIGH"}],"browseBranches":[{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Ot","name":"Other Dietary Supplements"}]}},"hasResults":false}